With $9.5M, Intrepida Bio Launches to Target Pancreatic Cancer & More

Dauntless Pharmaceuticals formed in 2016, and its founders said the Sofinnova Ventures-backed firm planned to take a new approach to building biotechs. Instead of advancing a broad stable of early-stage drug candidates under the same roof, Dauntless aimed to set up each asset within its own company. The idea was that when it came time [?]